

FibroScan[®]

mini+ 430 by echosens

**The mobile non-invasive solution
for liver disease management,
ideal for multi-site configuration**



The mobile non-invasive solution for liver disease management, ideal for multi-site configuration

Designed for multi-centers sharing and remote liver patients management.

Powered by

LSM* by VCTE™

Liver Fibrosis

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment.

- It is the standard for non-invasive evaluation of liver stiffness.¹
- 2,250 peer-reviewed publications support the use of LSM by VCTE™.

CAP™**

Liver Steatosis

CAP™ is unique, patented and validated for liver steatosis assessment.

- 330 international and peer-reviewed articles support the use of CAP™.^{2,3}



Smartly adaptable to all settings

Light and easy to handle (5 kg)

Battery-powered device

12.1 inches touch screen

2 probe connectors to easily switch between the M+ and XL+ probe during the examination

Provided with airplane compatible transport suitcase



reddot award 2017 winner

What makes FibroScan® unique?

Fast

A painless exam performed in less than 10 minutes to provide immediate results at the point-of-care.

Intuitive

Can be performed by any trained operator (physician, nurse).

Best in Class

The non-invasive gold standard solution validated by 2,400+ peer-reviewed publications and 60+ international guidelines.

Reliable

Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients.^{2,3}

Original

Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.

When evidence matters and consistency counts

- **Pioneer** in the field of liver elastography
- FibroScan® produces biomarkers that can assess and monitor patients **over time**
- FibroScan® uses uniform algorithms that minimize **inter-operator variability** and eliminate **inter-system variability**
- **6,500+** FibroScan® installed worldwide enabling millions of liver examinations
- Winner of the Red Dot Design Award (FibroScan® 430 Mini+ model)



*LSM: Liver Stiffness Measurement.
**Additional cost.

Optimize clinical workflows with real-time secure data transmission

Save time, secure data, and improve patient follow-up with FibroScan[®] Gateway. FibroScan[®] Gateway acts as an integration engine, automatically uploading and storing examinations to the EHR (Electronic Health Record).



Scores
by echosens



Enhancing FibroScan[®] liver disease assessment with biological markers

FAST[™]

The optimal point-of-care comprehensive test for the identification of at risk NASH patients

FIBROMETER VCTE[™]

Cutting-edge liver fibrosis assessment with FibroScan[®] and biological markers

FIBROMETER[™]

The benchmark blood test for liver fibrosis diagnosis and disease stratification

Interpretation Guide

Enhanced clinical decision support

The Interpretation Guides utilize data from clinical studies to assist providers in interpreting FibroScan[®] examination results.

- Available on -



MyFibroScan

Your everyday FibroScan[®] companion



The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan[®] is right for you?



Capabilities	FibroScan [®] mini 430	FibroScan [®] mini+ 430	FibroScan [®] compact 530	FibroScan [®] expert 630
LSM by VCTE [™]	✓	✓	✓	✓
CAP ^{™*}		✓	✓	✓
SSM by VCTE [™]				✓
Features				
FibroScan [®] Gateway compatibility	✓	✓	✓	✓
MyFibroScan [®] compatibility	✓	✓	✓	✓
Embedded ultrasound localization system for assessment of obese or complex patients				✓
High-speed processing				✓
Integrated barcode reader				✓
Ergonomics				
Versatile and adaptive design: from transportable to cart-based device with dedicated roll stand			✓	
Fully transportable	✓	✓		
Battery-powered	✓	✓	✓	
Weight	5 kg	5 kg	10 kg	46 kg

*Additional cost



because liver health matters

1. European Association for Study of Liver, Asociación Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
 2. Wong VW-S, Adams LA, de Lédinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. doi:10.1038/s41575-018-0014-9
 3. Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158. doi:10.1155/2013/684982

Products in the FibroScan[®] range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan[®] device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Products FibroMeter[™] FibroMeter VCTE[™] and FAST[™] are in vitro diagnostic medical devices as defined by Directive 98/79/EC. These scores, based on blood parameters, are useful tools for diagnosing and measuring the extent of liver fibrosis in patients with chronic liver disease of viral (including HIV co-infection), alcohol-related, or metabolic origin. FibroMeter[™], FibroMeter VCTE[™] FAST[™] and FibroScan[®] are registered trademarks of Echosens. This marketing material is not intended for US audience. © Copyright Echosens - All rights reserved - Brochure FibroScan[®] 430 Mini+ v10720